Healthcare -
Biotechnology - NASDAQ - US
$ 0.0535
-0.926 %
$ 2.5 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
Reviva Pharmaceuticals Holdings, Inc.
| Current Assets | 14.7 M |
| Cash & Short-Term Investments | 13.5 M |
| Receivables | 0 |
| Other Current Assets | 1.21 M |
| Non-Current Assets | 820 K |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 820 K |
| Current Liabilities | 14.6 M |
| Accounts Payable | 6.28 M |
| Short-Term Debt | 458 K |
| Other Current Liabilities | 7.86 M |
| Non-Current Liabilities | 89 K |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 89 K |
EFFICIENCY
Earnings Waterfall
Reviva Pharmaceuticals Holdings, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 30.8 M |
| Operating Income | -30.8 M |
| Other Expenses | -880 K |
| Net Income | -29.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Reviva Pharmaceuticals Holdings, Inc.
| Net Income | -29.9 M |
| Depreciation & Amortization | 0 |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.63 M |
| Change in Working Capital | -4.54 M |
| Others | -7.55 M |
| Free Cash Flow | -33.5 M |
Wall Street Analysts Price Targets
Reviva Pharmaceuticals Holdings, Inc.
RVPHW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
RVPHW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Reviva Pharmaceuticals Holdings, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
Reviva Pharmaceuticals Holdings, Inc. RVPHW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 2.5 M
Dividend Yield
0.00%
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.
Contact
19925 Stevens Creek Boulevard, Cupertino, DE, 95014
https://www.revivapharma.com
IPO
Date
None
Employees
14
Officers
Mr. Narayan Prabhu
Chief Financial Officer
Dr. Laxminarayan Bhat Ph.D.
Founder, Chief Executive Officer, President & Director